HLA-C and hepatocellular carcinoma: In addition, safety can be further enhanced when implementing HBV-TCR T-cell therapy in cases of HCC recurrence post-liver transplantation by the careful selection of HBV-TCRs recognizing HBV epitopes restricted by MHC molecules only present in the host and not on the donor liver graft.